azd3293
Small moleculeexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2012 (NCT01739647)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Beta-secretase 1INHIBITOR
BACE1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'h-dispiro(cyclohexane-1,2'-inden-1',2'-imidazol)-4'-amine
- azd3293
- azd3293
- azd3293
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02126514 | Phase 1 | May 1, 2014 | AstraZeneca, Covance |
| NCT02039180 | Phase 1 | Feb 1, 2014 | AstraZeneca |
| NCT02040987 | Phase 1 | Jan 1, 2014 | AstraZeneca, Parexel |
| NCT02010970 | Phase 1 | Dec 1, 2013 | AstraZeneca, WCCT Global |
| NCT02005211 | Phase 1 | Dec 1, 2013 | AstraZeneca, Sugioka Memorial Hospital |
| NCT01795339 | Phase 1 | Mar 1, 2013 | AstraZeneca, Parexel |
| NCT01739647 | Phase 1 | Dec 1, 2012 | AstraZeneca, Parexel |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 7 | 7 | 1 | 2012 |
| Parexel | For profit | 3 | 0 | 1 | 2012 |
| Covance | For profit | 1 | 0 | 1 | 2014 |
| Sugioka Memorial Hospital | Academic/Hospital | 1 | 0 | 1 | 2013 |
| WCCT Global | For profit | 1 | 0 | 1 | 2013 |
5 organizations
Page 1 / 1